Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

Trial Profile

A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin lispro/pramlintide (Primary) ; Insulin lispro; Pramlintide
  • Indications Type 1 diabetes mellitus
  • Focus First in man; Pharmacokinetics
  • Sponsors Adocia
  • Most Recent Events

    • 10 Sep 2019 According to an Adocia media release, results of this study will be presented at the upcoming 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), being held September 16-20, 2019 in Barcelona, Spain.
    • 10 Sep 2019 Results published in the Adocia Media Release
    • 11 Jun 2019 Safety and efficacy results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top